Abeona Therapeutics
ABEO
55 hedge funds and large institutions have $182M invested in Abeona Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 6 closing their positions.
1,241% more call options, than puts
Call options by funds: $4.08M | Put options by funds: $304K
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
42% more capital invested
Capital invested by funds: $128M → $182M (+$53.9M)
15% more funds holding
Funds holding: 48 → 55 (+7)
7.21% less ownership
Funds ownership: 73.59% → 66.38% (-7.2%)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.05M |
| 2 |
Citigroup
New York
|
+$660K |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$580K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$439K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$434K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$3.26M |
| 2 |
Morgan Stanley
New York
|
-$2.19M |
| 3 |
Millennium Management
New York
|
-$1.96M |
| 4 |
Renaissance Technologies
New York
|
-$1.93M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.05M |
ABEO Hedge Fund Activity: Q3 2024 in Review
55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2024, worth a combined $182M — up 42% from $128M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ABEO positions and 6 closed out — a net gain of 7 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $1.05M. The largest seller was Propel Bio Management, cutting an estimated $3.26M.
- 55 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2024, up from 48 in Q2 2024.
- Funds reported $182M of Abeona Therapeutics stock for Q3 2024, up 42% quarter-over-quarter.
- 13 funds opened new Abeona Therapeutics positions in Q3 2024 and 6 closed out, a net change of +7 holders.
- The largest Abeona Therapeutics buyer in Q3 2024 was Aberdeen Group, an estimated $1.05M added.
- The largest Abeona Therapeutics seller in Q3 2024 was Propel Bio Management, an estimated $3.26M sold.
Based on aggregated 13F filings for Q3 2024.